Cargando…
Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature
Historically, secondary amyloidosis has been a feared complication of chronic inflammatory conditions. The fibril protein AA derives from the acute phase reactant serum amyloid A (SAA). Long-term elevation of SAA levels remains a major risk factor for the development of AA amyloidosis in rheumatic d...
Autores principales: | Eriksson, Per, Mölne, Johan, Wirestam, Lina, Sjöwall, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107218/ https://www.ncbi.nlm.nih.gov/pubmed/33981717 http://dx.doi.org/10.3389/fmed.2021.661101 |
Ejemplares similares
-
OR14-001 – Tocilizumab in autoinflammation and AA amyloidosis
por: Lane, T, et al.
Publicado: (2013) -
Gout in the Chest Misdiagnosed as Ankylosing Spondylitis
por: Xue, Wenjing, et al.
Publicado: (2020) -
Thoracic Discitis in Ankylosing Spondylitis
por: Maloney, Eamon, et al.
Publicado: (2018) -
Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis
por: Matsui, Masaru, et al.
Publicado: (2014) -
Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
por: Yılmaz, Sedat, et al.
Publicado: (2018)